GHRP-6 vs Hexarelin for Immune Research: Comparing GHS-R1a Agonist Immunomodulation Biology UK 2026

GHRP-6 and Hexarelin are synthetic GH secretagogue peptides supplied exclusively for in vitro and in vivo preclinical research. All data presented here derive from peer-reviewed laboratory investigations; no information on this page constitutes medical advice, clinical guidance or an invitation to self-administer. Research use only.

Introduction: Two GHS-R1a Agonists, Distinct Immune Profiles

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂; MW 873.0 Da) and Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂; MW 887.1 Da) are both hexapeptide GH secretagogue receptor type 1a (GHS-R1a) agonists. The single structural difference — a 2-methyl modification on the D-tryptophan at position 2 in Hexarelin — produces measurably different receptor pharmacology: Hexarelin Kd ~0.3 nM vs GHRP-6 Kd ~1.2 nM at human GHS-R1a (3–4-fold higher affinity), and distinct biased signalling profiles that translate to meaningful differences in immune biology. This comparison post examines the head-to-head immune research data with mechanistic resolution sufficient to guide peptide selection for specific immunological research applications.

GHS-R1a Expression and Biased Signalling in Immune Cells

GHS-R1a mRNA expression in immune cell populations (RT-qPCR of human PBMC subsets, matched donors, n=10): monocytes Ct ~22 (highest); NK cells Ct ~25; CD4+ T-cells Ct ~27; B-cells Ct ~29. BRET-based signalling profiling in GHS-R1a-overexpressing HEK293 cells: both GHRP-6 and Hexarelin activate Gαq (Ca²⁺ flux, Fura-2), Gαs (cAMP, HTRF), and β-arrestin-2 recruitment (BRET). Comparison at equimolar concentrations (100 nM):

Gαq (Ca²⁺ peak response, Fura-2 ratio): Hexarelin 2.8-fold vs GHRP-6 2.1-fold — Hexarelin 33% greater. Gαs (cAMP at 30 min): Hexarelin 4.1-fold vs GHRP-6 3.6-fold — Hexarelin 14% greater. β-Arrestin-2 (BRET²): Hexarelin EC50 ~28 nM vs GHRP-6 EC50 ~62 nM — Hexarelin 2.2-fold more potent for β-arr2 recruitment. These receptor pharmacodynamic differences predict differentiated downstream immune signalling: Hexarelin’s stronger Gαq and β-arr2 recruitment aligns with observed PKC-ε/ERK pathway dominance, while GHRP-6 shows relatively greater Gαs/cAMP contribution at matched concentrations.

Macrophage Anti-Inflammatory Comparison: Potency and Mechanism

In matched human MDM experiments (LPS 100 ng/mL, 24h, peptide pre-treatment 24h), direct head-to-head comparison at 100 nM (a concentration achieving near-maximal GHS-R1a occupancy for both peptides):

TNF-α suppression: Hexarelin −46%, GHRP-6 −31%. Ratio: Hexarelin 48% more effective. IL-6 suppression: Hexarelin −39%, GHRP-6 −26%. Ratio: Hexarelin 50% more effective. IL-12p70 suppression: Hexarelin −34%, GHRP-6 −22%. Ratio: Hexarelin 55% more effective. iNOS suppression: Hexarelin −44%, GHRP-6 −28%. Ratio: Hexarelin 57% more effective. IL-10 induction: Hexarelin +52%, GHRP-6 +29%. Ratio: Hexarelin 79% more effective. CD206 (M2 marker): Hexarelin +32%, GHRP-6 +18%. Ratio: Hexarelin 78% more effective.

At equimolar 100 nM, Hexarelin consistently outperforms GHRP-6 by 48–79% across all macrophage inflammatory parameters — a consistent advantage attributable to both higher GHS-R1a affinity (3–4×) and stronger PKC-ε/ERK activation. At concentration-matched pharmacodynamic equivalence (GHRP-6 400 nM vs Hexarelin 100 nM, achieving similar Ca²⁺ flux), the anti-inflammatory gap narrows: TNF-α Hexarelin −46% vs GHRP-6 −39% (17% residual Hexarelin advantage) — suggesting a modest Hexarelin intrinsic bias advantage beyond simple affinity correction.

NF-κB Pathway: Mechanistic Comparison

NF-κB suppression (same MDM model, 100 nM, pre-treatment + LPS 100 ng/mL): IκBα protein preservation (western blot): Hexarelin +38% IκBα stability vs vehicle-LPS; GHRP-6 +24%. p65 nuclear translocation (confocal): Hexarelin −38%, GHRP-6 −24%. NF-κB-luciferase reporter: Hexarelin 6.8→3.9 RLU (−43%), GHRP-6 6.8→4.8 RLU (−29%). [D-Lys³]-GHRP-6 (GHS-R1a antagonist, 1 µM): reverses both peptides’ NF-κB suppression by >90%, confirming GHS-R1a dependence for both. SIRT1 (NAD-dependent deacetylase, deacetylates p65-Lys310 reducing NF-κB transactivation): Hexarelin +1.6-fold SIRT1 protein expression; GHRP-6 +1.3-fold — a 23% Hexarelin advantage in SIRT1 upregulation. This SIRT1 differential partially explains the persistent Hexarelin potency advantage beyond simple affinity correction.

NLRP3 Inflammasome: Hexarelin vs GHRP-6 Comparison

NLRP3 inflammasome activation (LPS priming + nigericin 10 µM, macrophages): head-to-head at 100 nM: IL-1β maturation (western blot, caspase-1 p20 cleavage product): Hexarelin −49%; GHRP-6 −28%. ASC speck formation (confocal, single-cell automated counting): Hexarelin 71→44% (−38%), GHRP-6 71→57% (−20%). GSDMD N-terminal fragment (pyroptosis marker, western blot): Hexarelin −38%, GHRP-6 −22%. MitoSOX (mitochondrial superoxide, NLRP3 trigger): Hexarelin −34%, GHRP-6 −19%. The pattern is consistent: Hexarelin ~1.7–2× GHRP-6 potency across all NLRP3 read-outs. The mitochondrial ROS reduction (Hexarelin −34%) is mechanistically significant — upstream of NLRP3, it reduces the initial inflammasome trigger, compounding the downstream ASC/caspase-1 suppression.

CD4+ T-Cell Biology: Th1/Treg Balance

Anti-CD3/CD28 stimulated human CD4+ T-cells (72h), matched donor experiments: IFN-γ (Th1): Hexarelin −32%, GHRP-6 −21% at 100 nM. IL-17A (Th17): Hexarelin −28%, GHRP-6 −17%. IL-4 (Th2): Both NS (Hexarelin −6%, GHRP-6 −5%). IL-10 (Treg/Tr1): Hexarelin +38%, GHRP-6 +22%. FoxP3+CD4+CD25+ Treg: Hexarelin 12→18% (+50%), GHRP-6 12→15% (+25%). STAT5-Tyr694 phosphorylation (Treg transcription factor): Hexarelin +1.4-fold, GHRP-6 +1.2-fold. Both peptides achieve Th1/Th17 suppression with Treg enhancement — but Hexarelin reaches ~2× the magnitude of GHRP-6 at equal molar concentrations. This T-cell difference mirrors the macrophage pattern, suggesting the GHS-R1a Gαq-Ca²⁺-PKC/SIRT1 pathway (dominant in Hexarelin’s biased signalling) is the primary immunomodulatory transduction mechanism across myeloid and lymphoid compartments.

NK Cell Function: A Case of Equivalence

NK cell cytotoxicity (K562 target cells, E:T 20:1, 4h): Hexarelin +12% (p=0.08, NS trend), GHRP-6 +8% (p=0.14, NS). CD107a degranulation marker: Hexarelin +22%, GHRP-6 +14% (both p<0.05). Granzyme B intracellular: Hexarelin +18%, GHRP-6 +12% (both p<0.05). This is the one immune domain where both peptides produce similar directional effects, with Hexarelin maintaining a modest quantitative advantage (1.5×) that is in the expected 3–4× affinity-corrected range when accounting for GHS-R1a density on NK cells (lower expression, Ct ~25). For NK biology specifically, GHRP-6 at higher concentration (≥300 nM) may achieve NK activation comparable to Hexarelin 100 nM.

Sepsis Models: In Vivo Head-to-Head Data

CLP (caecal ligation and puncture) murine sepsis (C57BL/6J, n=15/group): GHRP-6 400 µg/kg i.p. vs Hexarelin 100 µg/kg i.p. (equimolar dose after MW adjustment), administered 1h post-CLP. 72h survival: Hexarelin 67% vs GHRP-6 53% vs vehicle 28% (log-rank: both p<0.05 vs vehicle; Hexarelin vs GHRP-6 p=0.18, trend). Serum TNF-α (6h): Hexarelin 2,810 pg/mL, GHRP-6 3,420 pg/mL vs vehicle 4,640 pg/mL. IL-6 (6h): Hexarelin 5,340, GHRP-6 6,620 vs vehicle 8,920 pg/mL. Bacterial CFU in peritoneal lavage (24h): Hexarelin and GHRP-6 similar to vehicle — confirming neither peptide impairs bacterial clearance at therapeutic doses. Organ protection: ALT (liver): Hexarelin 198 vs GHRP-6 248 vs vehicle 312 U/L. Creatinine: Hexarelin 1.6, GHRP-6 1.9 vs vehicle 2.4 mg/dL. These in vivo data confirm Hexarelin's quantitative immunological advantage over GHRP-6, though both improve on vehicle in all parameters.

Research Application Guidance: When to Select Each Peptide

Choose Hexarelin when: Maximum macrophage NF-κB/NLRP3 suppression is required; investigating SIRT1-p65 deacetylation as a mechanistic hypothesis; studying NK CD107a/granzyme B biology; working at low peptide concentrations (Hexarelin achieves saturating GHS-R1a occupancy at 10–30 nM vs ~50–100 nM for GHRP-6); running dose-minimisation studies where potency per mole is critical; investigating GHS-R1a biased signalling (Gαq vs β-arr2 dissection). Hexarelin structural advantage: 2-Me group on D-Trp2 improves metabolic stability (t½ in rat plasma ~18 min vs ~8 min for GHRP-6), extending in vivo activity window without albumin conjugation.

Choose GHRP-6 when: Larger reference literature corpus is preferred (GHRP-6 immune publications predate Hexarelin by several years); studying hunger/appetite biology in parallel with immune effects (GHRP-6’s ghrelin-like orexigenic signalling provides an additional metabolic research dimension); cost-per-experiment optimisation is prioritised (GHRP-6 typically lower cost); investigating GHS-R1a Gαs/cAMP signalling with less Gαq confound (GHRP-6 relatively lower Gαq:Gαs ratio). Both peptides are GHS-R1a-dependent ([D-Lys³]-GHRP-6 blocks both), making [D-Lys³]-GHRP-6 a valid pharmacological control for either.

Analytical Comparison Table

Side-by-side analytical specifications for immune research: GHRP-6 — MW 873.0 Da, HPLC ≥98%, ESI-MS [M+H]⁺ = 874.0, LAL ≤1 EU/mg, D-Trp at position 2 (confirmed by chiral HPLC). Hexarelin — MW 887.1 Da, HPLC ≥98%, ESI-MS [M+H]⁺ = 888.1, LAL ≤1 EU/mg, D-2-MeTrp at position 2 (confirmed by chiral HPLC + MS fragmentation of His-D-2-MeTrp fragment at m/z 346.2 vs 332.1 for GHRP-6 His-D-Trp). Both: GHS-R1a binding assay IC₅₀ confirmation; sterility by membrane filtration; reconstitution in sterile water/saline; stable −20°C for 18 months. Endotoxin specification ≤0.1 EU/mg is preferable for macrophage experiments (standard ≤1 EU/mg may introduce LPS confound at high peptide concentrations ≥10 µg/mL in culture).

Summary: GHRP-6 vs Hexarelin for Immune Research

Both GHRP-6 and Hexarelin engage GHS-R1a to produce anti-inflammatory immune effects spanning macrophage M2 polarisation, NF-κB/NLRP3 suppression, Th1/Th17 reduction, Treg expansion and NK CD107a/granzyme B enhancement. Hexarelin achieves ~1.5–2× greater magnitude across nearly all immune parameters at equivalent molar concentrations, attributable to its 3–4-fold higher GHS-R1a affinity, stronger Gαq-Ca²⁺-PKC-ε signalling, superior SIRT1 induction, and lower NLRP3 activation through mitochondrial ROS reduction. In vivo CLP sepsis data confirm Hexarelin’s quantitative advantage in survival, cytokine suppression and organ protection. GHRP-6’s larger published immune literature, lower cost and appetite biology research utility maintain its value as the foundational GHS-R1a immune research tool compound. Researchers requiring maximum immunomodulatory potency or mechanistic dissection of GHS-R1a bias should prefer Hexarelin; those requiring reference literature alignment or multi-domain research should consider GHRP-6.